Ludwig Enterprises Inc. (LUDG)
OTC PINK OTC PINK Primary 
Ludwig Enterprises Begins PCR Validation Test Process
Final step before the full launch of breast cancer screening program, Revealia™ SPARKS, NV / ACCESSWIRE / November 7, 2024 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), a leading USA-based biotechnology company (the "Company"), has retained an independent lab in Florida that will conduct a third-party validation process for the Company's PCR (Polymerase Chain Reaction) breast cancer screening program, Revealia™. Once the validation protocols have been established and testing completed, Revealia™ will begin its nationwide launch.
Ludwig Enterprises Files Provisional Patent for Revolutionary Cancer Screening Algorithm, Plans 2024 Launch as Revealia(TM)
SPARKS, NV / ACCESSWIRE / October 24, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a leading USA-based biotechnology company, has filed a provisional patent for its breakthrough cancer detection method titled "mRNAs Differentially Expressed in Cancer." The company's latest innovation, which analyzes a six-mRNA gene combination, has demonstrated a significant increase in sensitivity and specificity for breast cancer detection, compared to previous methods.
CORRECTING AND REPLACING: Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology
This press release replaces the release issued today at 9:15am EDT. Revolutionary AI-driven cheek swab test poised to transform early cancer detection with continuously improving accuracy.
Ludwig Enterprises Inc. Announces AI-Powered Cancer Screening Technology
Revolutionary AI-driven cheek swab test poised to transform early cancer detection with continuously improving accuracy. Revealia™: A Breakthrough in Cancer Detection through Advanced AI and Machine Learning SPARKS, NV / ACCESSWIRE / September 24, 2024 / Ludwig Enterprises, Inc. (OTC PINK:LUDG), a USA based biotechnology company is pleased to announce Revealia™, which is set to become the world's most convenient cancer screening tool.
Ludwig Announces Acquisition of Intellectual Property and Patent
SPARKS, NV / ACCESSWIRE / September 17, 2024 / Ludwig Enterprises, Inc., (OTC PINK:LUDG), a USA-based biotechnology company, is pleased to announce it has acquired all the intellectual property and patent of the mRNA Neuro Panel and Serotonin Assay, along with all the data accumulated testing these Assays. Significance of acquisition: Allows use of mRNA genetic biomarkers to study inflammatory changes in the brain in such diseases as autism, post-traumatic stress disorder (PTSD), Parkinson's disease, Alzheimer's disease, multiple sclerosis, ALS, etc.
Ludwig Announces Substantial Corporate Initiatives
Revealia™, the world's most convenient cancer screening test, to launch in 2024 SPARKS, NV / ACCESSWIRE / August 14, 2024 / Ludwig Enterprises, Inc, (OTC PINK:LUDG), a USA-based biotechnology company, is pleased to announce its corporate vision for the next 120 days. Ludwig has embarked on a plan to reshape the Company as it nears its launch of Revealia™.
